Latest News - Thailand

 
Show/hide duplicate news articles.
Filter by countryfromabout
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Thursday, March 30, 2017

4:43:00 AM CEST

Subscribe
RSS

Language Selection

For any category/filter, users can choose:

  1. the language of the categorized news items (e.g. fr and de to display only those news items in French and German)
  2. the language of the user interface (e.g. it for Italian)

In Top Stories, the user can display the largest clusters of news items for one language only (e.g. en shows all clusters in English)

Country Selection

Users can choose:

  1. country mentioned in the news item (articles about a country)
  2. country in which the news item was published (articles from a country)

Languages Collapse menu...Expand menu...Open help...

Select your languages

ar
az
be
bg
bs
ca
cs
da
de
el
en
eo
es
et
fa
fi
fr
ga
ha
he
hi
hr
hu
hy
id
is
it
ja
ka
km
ko
ku
lb
lo
lt
lv
mk
mt
nl
no
pap
pl
ps
pt
ro
ru
rw
se
sk
sl
sq
sr
sv
sw
ta
th
tr
uk
ur
vi
zh
all
Show additional languagesHide additional languages

Interface:

Country info

TH

Thailand (TH)

All news about Thailand

All news sources from Thailand

TH

AlertLevel (24h)

Alert level graph

 Previous 14 days average

Alert level:
 high   medium   low

Quotes... Extracted quotes

Mitchell Warren says: “This new trial adds additional boosting doses to the original regimen, so hopefully we will see higher rates of protection in HVTN702 that might lead to licensure” External link

lancet Wednesday, March 29, 2017 2:40:00 AM CEST

Mitchell Warren explains: “The Janssen Ad26 vaccine program is a welcome addition to the field for several reasons. First, the product: the hope for a mosaic immunogen is that it would teach the immune system to block many viral strains, as opposed to HVTN702 which is subtype-C-specific. This would reduce the chance that HIV would escape from vaccine-induced protection” “Second, the role of industry: while many vaccine companies are engaged in HIV vaccine research and development (including Sanofi Pasteur and GlaxoSmithKline in HVTN702), it has been a number of years since a big pharmaceutical company has invested its own resources as Janssen and Johnson & Johnson are doing in driving forward both the development and clinical testing of this product. Finally, the partnership: the Ad26 program is leveraging diverse expertise and funding, involving pharma, public and philanthropic funders; academic researchers (who led the initial development); and all of the major clinical trial networks. Of course, we don't know if this vaccine will work, but it is certainly pioneering efforts on many fronts” External link

lancet Wednesday, March 29, 2017 2:40:00 AM CEST

Mitchell Warren says: “These infusion trials are proof of concept studies to see if the antibody can prevent infection, and, if they do, they will inform vaccine development. There are now multiple antibodies being studied and the combination of these approaches along with classic vaccine immunogens make for an exciting scientific time” “It is critical now to continue investment in these and other new vaccine and non-vaccine prevention strategies. We have to simultaneously accelerate delivery of existing prevention and treatment options that will continue to reduce incidence in the coming years, but it will only be a vaccine that can sustainably control the epidemic” External link

lancet Wednesday, March 29, 2017 2:40:00 AM CEST

Lynn Morris explains: “VRC01 will be directly infused into the bloodstream of human volunteers to determine if it can protect against HIV infection and what levels of antibody are needed” External link

lancet Wednesday, March 29, 2017 2:40:00 AM CEST

Øivind Nilsen sier: - Gonoréforekomsten i den generelle befolkningen har nå nådd et nivå der vi frykter at vi igjen kan stå overfor en mer omfattende spredning av gonoré i Norge slik de nå opplever i mange andre land, blant annet i Danmark og Sverige, External link

dagbladet Wednesday, March 15, 2017 11:50:00 AM CET

Øivind Nilsen sier: - Antibiotikaresistente gonokokker er et raskt økende problem, og internasjonalt er det nå stor bekymring for resistenssituasjonen i lys av den økende forekomsten av gonoré, External link

dagbladet Wednesday, March 15, 2017 11:50:00 AM CET

Øivind Nilsen sier: – Gonoréforekomsten i den generelle befolkningen har nå nådd et nivå der vi frykter at vi igjen kan stå overfor en mer omfattende spredning av gonoré i Norge slik de nå opplever i mange andre land, blant annet i Danmark og Sverige, External link

fhi Wednesday, March 15, 2017 10:07:00 AM CET

Øivind Nilsen sier: – Antibiotikaresistente gonokokker er et raskt økende problem, og internasjonalt er det nå stor bekymring for resistenssituasjonen i lys av den økende forekomsten av gonoré, External link

fhi Wednesday, March 15, 2017 10:07:00 AM CET

Øivind Nilsen sier: – Økt kondombruk, effektiv diagnostikk og behandling, omhyggelig smitteoppsporing og rask lokal intervensjon ved utbrudd er avgjørende for å holde disse infeksjonene under god kontroll i Norge, External link

fhi Wednesday, March 15, 2017 10:07:00 AM CET

Themes

Country themes

Daily number of articles in this category

Trend data not available for this selection.